ATHERSYS INC (ATHX) Stock Price, Forecast & Analysis
USA - NASDAQ:ATHX - US04744L2051 - Common Stock
ATHX Key Statistics, Chart & Performance
The current stock price of ATHX is 0.1018 USD. In the past month the price decreased by -67.28%. In the past year, price decreased by -94.94%.
ATHX Latest News, Press Relases and Analysis
ATHX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About ATHX
Company Profile
Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. The company is headquartered in Cleveland, Ohio and currently employs 24 full-time employees. The company went IPO on 2007-04-23. The firm is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
Company Info
ATHERSYS INC
3201 Carnegie Ave
CLEVELAND OHIO 44115 US
CEO: William Lehmann Jr.
Employees: 24
Phone: 12164319900.0
ATHERSYS INC / ATHX FAQ
What does ATHERSYS INC do?
Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. The company is headquartered in Cleveland, Ohio and currently employs 24 full-time employees. The company went IPO on 2007-04-23. The firm is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
What is the stock price of ATHERSYS INC today?
The current stock price of ATHX is 0.1018 USD. The price increased by 3.77% in the last trading session.
Does ATHERSYS INC pay dividends?
ATHX does not pay a dividend.
How is the ChartMill rating for ATHERSYS INC?
ATHX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of ATHERSYS INC (ATHX) based on its PE ratio?
ATHERSYS INC (ATHX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.03).
Would investing in ATHERSYS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ATHX.
ATHX Technical Analysis
ATHX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ATHX. Both the profitability and financial health of ATHX have multiple concerns.
ATHX Financial Highlights
Over the last trailing twelve months ATHX reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 64.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -452.29% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATHX Forecast & Estimates
7 analysts have analysed ATHX and the average price target is 5.61 USD. This implies a price increase of 5410.81% is expected in the next year compared to the current price of 0.1018.
For the next year, analysts expect an EPS growth of 83.47% and a revenue growth -100% for ATHX